Sallet G
Department of Ophthalmology, Aalsters Stedelijk Ziekenhuis, Aalst, Belgium.
Bull Soc Belge Ophtalmol. 2006(299):67-73.
Evaluation of the results of the first 30 patients, bilaterally implanted with the bifocal Acrysof Restor Apodized Diffractive intraocular lens (IOL) (SA60D3). The optics of this lens are designed to restore near and distance vision.
Department of Ophthalmology, Aalsters Stedelijk Ziekenhuis, Aalst, Belgium.
Sixty eyes of 30 patients had implantation of the Alcon Acrysof Restor SA60D3 IOL in this prospective nonrandomized clinical study. Fourty-eight eyes were evaluated at 6 months and 60 eyes at 3 months. Patient selection included no other eye disease besides cataract and corneal astigmatism of one diopter or less. Uncorrected distance visual acuity (UCVA-D), uncorrected near visual acuity (UCVAN), best corrected distance visual acuity (BCVA-D) and distance corrected near visual acuity (DCVA-N) were recorded. Glare phenomena, halos and night vision difficulties were evaluated as well as patient satisfaction.
Postoperative UCVA-D was better than 20/ 40 at 3 months and better than 20/30 at 6 months in all eyes. UCVA-N was equal or better than Jaeger (J) 3 at 3 months in 91% and all eyes achieved J3 or better at 6 months. BCVA-D was 20/30 or better in all eyes at 3 months and 20/25 or better at 6 months. DCVA-N was J2 or better in all eyes at 3 and 6 months. Patient satisfaction was excellent (76%), good (10%) or acceptable (14%). No patient was dissatisfied with the result. Twenty percent of patients mentioned glare or halos when specifically asked.
3- and 6-month data indicate that the Acrysof Restor Apodized diffractive IOL (SA60D3) provides excellent near visual acuity without compromising distance visual acuity. The incidence of visual disturbances is low and patient satisfaction high.
评估首批30例双眼植入双焦点Acrysof Restor变迹衍射人工晶状体(IOL)(SA60D3)的患者的结果。该晶状体的光学设计旨在恢复近视力和远视力。
比利时阿尔斯特市阿尔斯特市立医院眼科。
在这项前瞻性非随机临床研究中,30例患者的60只眼植入了爱尔康Acrysof Restor SA60D3 IOL。48只眼在6个月时进行评估,60只眼在3个月时进行评估。患者选择标准包括除白内障和1屈光度或更低的角膜散光外无其他眼病。记录未矫正远视力(UCVA-D)、未矫正近视力(UCVAN)、最佳矫正远视力(BCVA-D)和远矫正近视力(DCVA-N)。评估眩光现象、光晕和夜间视力困难以及患者满意度。
所有眼术后3个月时UCVA-D优于20/40,6个月时优于20/30。91%的眼术后3个月时UCVA-N等于或优于耶格(J)3,所有眼在6个月时均达到J3或更好。所有眼术后3个月时BCVA-D为20/30或更好,6个月时为20/25或更好。所有眼在3个月和6个月时DCVA-N为J2或更好。患者满意度为优秀(76%)、良好(10%)或可接受(14%)。没有患者对结果不满意。当特别询问时,20%的患者提到有眩光或光晕。
3个月和6个月的数据表明,Acrysof Restor变迹衍射IOL(SA60D3)可提供出色的近视力,而不影响远视力。视觉干扰的发生率低,患者满意度高。